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ID genes are required for breast cancer colonization
of the lungs, but the mechanism remains poorly un-
derstood. Here, we show that Id1 expression induces
a stem-like phenotype in breast cancer cells while re-
taining epithelial properties, contrary to the notion
that cancer stem-like properties are inextricably
linked to the mesenchymal state. During metastatic
colonization, Id1 induces a mesenchymal-to-epithe-
lial transition (MET), specifically in cells whose
mesenchymal state is dependent on the Id1 target
protein Twist1, but not at the primary site, where
this state is controlled by the zinc finger protein
Snail1. Knockdown of Id expression in metastasizing
cells prevents MET and dramatically reduces lung
colonization. Furthermore, Id1 is induced by trans-
forming growth factor (TGF)-b only in cells that
have first undergone epithelial-to-mesenchymal
transition (EMT), demonstrating that EMT is a prereq-
uisite for subsequent Id1-induced MET during lung
colonization. Collectively, these studies underscore
the importance of Id-mediated phenotypic switching
during distinct stages of breast cancer metastasis.
INTRODUCTION
Metastasis accounts for 90%of carcinoma-related deaths, mak-
ing a detailed understanding of this complex phenomenon
essential in reducing the lethality of this disease (Gupta andMas-
sague´, 2006). The multistep process of metastasis can be orga-
nized into two major phases: (1) physical dissemination of the
cancer cell from its site of origin and (2) colonization of distant1228 Cell Reports 5, 1228–1242, December 12, 2013 ª2013 The Autorgans (Chaffer and Weinberg, 2011). The first phase is accom-
panied by reactivation of the developmental program called the
epithelial-to-mesenchymal transition (EMT), which endows can-
cer cells with a highly invasive phenotype (Thiery et al., 2009).
During EMT, immobile epithelial cells lose their epithelial traits
and acquire mesenchymal properties and the ability to migrate.
The importance of EMT in metastasis is supported by findings
showing that cancer cells that have undergone EMT share key
characteristics with tumor initiating cells (TICs) (Mani et al.,
2008), which are functionally defined by their ability to seed
new tumors and restore the heterogeneity of the original tumor
(Dick, 2008). The generation of breast cancer TICs by the over-
expression of EMT-inducing transcription factors, such as
Twist1 (Mani et al., 2008), has provided a direct molecular link
between EMT-driven metastatic dissemination and the genera-
tion of TICs. However, less is known about the biology of TICs
during the second phase of metastasis, the colonization of
distant organs.
The idea that breast cancer TICs that colonize the lung perma-
nently retain their mesenchymal character has been challenged
by clinical observations showing most metastases present a
differentiated epithelial morphology (Tarin et al., 2005). This sug-
gests that EMT is a transient process and that the redifferentia-
tion of carcinoma cells by a ‘‘mesenchymal to epithelial transi-
tion’’ (MET) is a driving force of metastatic colonization at least
in some cancers (Brabletz, 2012). Although EMT governs
different steps during cancer cell dissemination, including inva-
sion of the local parenchyma, intravasation into the circulatory
system, survival during migration, and finally extravasation into
the secondary site, the loss of a mesenchymal phenotype may
enhance the formation of macrometastatic colonies, in part by
overcoming the growth arrest associated with EMT (Brabletz
et al., 2001; Vega et al., 2004). Evidence for the importance of
MET in breast cancer metastasis has been provided by studies
showing that, after dissemination, engineered loss of the EMThors
transcription factor Twist1 (Tsai et al., 2012) and the expression
of microRNAs inhibiting the EMT transcription factors Zeb1/
Zeb2 (Korpal et al., 2011) enhance lung colonization of meta-
static breast cancer cells. Furthermore, the transcription factor
Prrx1, which induces EMT during dissemination but suppresses
stemness traits necessary for lung colonization (Ocan˜a et al.,
2012), must be lost prior to colonization, uncoupling in this
instance EMT from the TIC phenotype. However, the details of
how a colonizing cancer cell sheds its mesenchymal phenotype
while retaining the TIC properties that promote its ability to serve
as a founder for a metastatic colony remain unclear.
Comparison of gene expression data between cell lines and
their derivatives with variable metastatic potential has led to
the identification of candidate genes required for the metastatic
cascade (Minn et al., 2005). Such analyses showed that the
expression of the ID1 and ID3 genes was essential during lung
colonization of breast cancer cells (Gupta et al., 2007). The Id
(Inhibitor of DNA-binding) proteins are dominant-negative regu-
lators of basic helix-loop-helix (bHLH) transcription factors (Perk
et al., 2005). During development, Id proteins play a key role in
the maintenance of embryonic stem cell self-renewal (Romero-
Lanman et al., 2012; Ying et al., 2003), and they continue to serve
this function in many adult tissue stem cells, including neural
(Nam and Benezra, 2009) and hematopoietic stem cells (Jan-
kovic et al., 2007). ID genes have also been implicated as key
regulators of the TIC phenotype in glioblastoma (Anido et al.,
2010; Barrett et al., 2012) and colon cancer (O’Brien et al.,
2012). The role of Id proteins in breast cancer metastasis and
their importance in self-renewal make them prime candidates
for the study of stem cell character as it relates to metastatic
colonization of breast cancer cells.
bHLH transcription factors act as obligate dimers, usually
formed between ubiquitously expressed E proteins and tissue-
specific bHLH proteins, such as Twist1 (Perk et al., 2005; Spicer
et al., 1996). Id proteins lack the basic DNA binding motif and
thus negatively regulate bHLH transcription factors upon the
formation of heterodimers (Ruzinova and Benezra, 2003). During
cranial fusion in developing mouse embryos, Id1 regulates the
differentiation state of cells found in osteogenic fronts by con-
trolling the dimerization of Twist1 and E proteins (Connerney
et al., 2006). However, the functional and regulatory role of Id
proteins in the context of EMT-driven metastasis induced by
bHLH transcription factors such as Twist1 remains to be
elucidated.
In human breast cancer, Id1 is predominantly expressed in the
more aggressive triple-negative (negative for estrogen receptor,
progesterone and HER2) and metaplastic subtype, with high
expression correlating with poor clinical outcome (Gupta et al.,
2007). The mechanism by which Id1 is induced in breast cancer
cells is not understood. In glioblastoma, the cytokine transform-
ing growth factor (TGF)-b is required to maintain the TIC popula-
tion through the upregulation of Id1 and Id3 (Anido et al., 2010).
TGF-b plays a similar role as a component of an autocrine
signaling program that controls self-renewal in normal and
malignant breast cancer cells (Scheel et al., 2011). Although
TGF-b represses Id1 expression in normal epithelial cells (Kang
et al., 2003), TGF-b induces Id1 in breast cancer cells derived
from the pleural effusion fluid of patients with metastatic diseaseCell Re(Padua et al., 2008). This divergent effect of TGF-b parallels the
dichotomous role of TGF-b as a tumor suppressor early in cancer
formation versus a metastasis enhancer in late cancer progres-
sion (Massague´, 2012).
In this report, we examine the ability of Id1 to induce breast
cancer TICs necessary for seeding new tumors during pulmo-
nary colonization. We hypothesize that Id1 governsMET through
antagonism of the bHLH transcription factor Twist without the
loss of the TIC phenotype that is required for metastatic coloni-
zation. We also examine how Id1 is induced in disseminated
breast cancer cells by investigating the regulation of Id1 by
TGF-b in TICs.
RESULTS
Id1 Induces Tumor-Initiating Properties Independently
of EMT
To determine whether Id1 can induce a TIC phenotype in human
mammary cells, Id1 was overexpressed in immortalized human
mammary epithelial cells (HMLEs) (Figure S1A) (Elenbaas et al.,
2001). Generation of TICs by expression of the transcription
factors Snail1 and Twist1 has been previously described in
HMLEs (Mani et al., 2008). HMLE cells transduced with an ID1
lentivirus vector (HMLE-Id1) were examined for TIC enrichment
using flow cytometry analysis of CD44 and CD24 cell-surface
marker expression (Al-Hajj et al., 2003). HMLE-Id1 cells acquired
a 2-fold enrichment in the CD44high/CD24low-expressing sub-
population compared to control cells (Figure 1A). An increase
in the same antigenic phenotype was observed in cells express-
ing Snail and Twist (Figure 1A) as previously reported (Mani et al.,
2008).
Self-renewing normal mammary and breast cancer cells form
mammospheres in suspension culture (Dontu et al., 2003; Ponti
et al., 2005). Similar to Twist or Snail, Id1 expression conferred
HMLE cells with a higher capacity to form mammospheres
compared to control HMLE cells (Figure 1B). However, HMLE-
Id1 mammospheres had smaller diameters and more defined
borders compared to HMLE-Twist mammospheres (Figure 1C),
although no differences in proliferation were observed between
them when grown under adherent conditions (Figure S1B). This
discrepancy could be due to the epithelial nature of HMLE-Id1
mammospheres as evidenced by expression of epithelial
markers E-cadherin and membrane bound b-catenin (Figure 1D)
with aminority of cells staining positively for Vimentin (Figure 1D).
In contrast, HMLE-Twist mammospheres were mostly positive
for Vimentin with a minority of cells expressing E-cadherin
(Figure S1C).
Recent studies have shown a correlation between the expres-
sion of several EMT-inducing embryonic transcription factors,
such as Snail (Mani et al., 2008), Slug (Guo et al., 2012), Twist1
(Mani et al., 2008), and Zeb1/Zeb2 (Eger et al., 2005), and the in-
duction of TICs in breast cancer cells. Because Id1 induces
mammospheres with an epithelial phenotype, we next examined
if Id1 induces TICs independently of EMT. HMLE-Id1 cells did not
change their epithelial morphology compared to control HMLE
cells (Figure 1E), whereas HMLE-Twist cells underwent typical
morphological changes accompanying EMT: they acquired
a spindle-like shape and formed few contacts betweenports 5, 1228–1242, December 12, 2013 ª2013 The Authors 1229
Figure 1. HMLE-Id1 Cells Exhibit Tumor-
Initiating Properties Independently of EMT
(A) Quantification of FACS analysis for cell-surface
markers CD44 and CD24 in HMLE cells express-
ing control vector, Snail, Twist1, and Id1.
(B) Quantification of mammospheres formed by
cells described in (A).
(C) Mammospheres formed by HMLE-Id1 and
HMLE-Twist cells. The scale bar represents
200 mm.
(D) Immunofluorescence (IF) images of mammo-
spheres formed by HMLE-Id1 cells stained for E-
cadherin, b-catenin, and Vimentin (white arrows).
The scale bar represents 200 mm.
(E) Parental HMLE cells express E-cadherin and
are negative for Vimentin (top row). HMLE cells
expressing Twist1 undergo EMT as seen by the
loss of E-cadherin and gain of Vimentin (middle
row). HMLE cells expressing Id1 express E-cad-
herin and are negative for Vimentin (bottom row).
The scale bar represents 100 mm.
(F and G) Tumor incidence (yellow arrows) of 105
control HMLERcells injected into themammary fat
pads of nude mice (F) compared to that of
HMLER-Id1 cells (G).
(H) Immunohistochemistry (IHC) performed on
tumors generated by HMLER-Id1 cells shows
positive staining for Id1 and E-cadherin, and
absence of Vimentin. The scale bar represents
200 mm.neighboring cells (Figure 1E). HMLE-Id1 cells continued to ex-
press the epithelial marker E-cadherin and were negative for
the mesenchymal marker Vimentin (Figures 1E and S1A). The
loss of E-cadherin and the gain of Vimentin expression are hall-
marks of EMT and are observed in HMLE-Twist cells (Figures 1E
and S1D). Thus, a dominant-negative transcriptional regulator
can induce a TIC phenotype in mammary cells independently
of the induction of EMT.
The standard in vivo assay for examining TIC properties of
cancer cells is the ability to form tumors in xenotransplantation
assays from limiting dilutions (Dick, 2008). Tumorigenicity of
V12H-Ras transformed HMLE cells expressing Id1 (HMLER-1230 Cell Reports 5, 1228–1242, December 12, 2013 ª2013 The AuthorsId1) (Elenbaas et al., 2001) wasmeasured
by injecting limiting dilutions of cells into
mammary fat pads of immune-compro-
mised mice. In vitro, HMLER-Id1 cells
displayed the same antigenic phenotype,
mammosphere formation properties, and
morphology as HMLE-Id1 cells (data not
shown). When 105 control HMLER cells
were injected into mammary fat pads,
only one of five mice developed palpable
tumors 1month after injection (Figures 1F
and S1E). In contrast, five of five animals
(p = 0.02) injected with HMLER-Id1 (Fig-
ures 1G and S1E) cells had visible tumors
1 month after injection, identical to
results obtained with HMLER-Twist and
HMLER-Snail cells (data not shown)(Mani et al., 2008). HMLER-Id1 tumors continued to express
the epithelial marker E-cadherin and did not express the mesen-
chymal marker Vimentin (Figure 1H). Notably, no lung metasta-
ses were detected 3 months after tumor cell injection when
mice were sacrificed due to heavy tumor burden at the primary
site. We speculate that HMLER-Id1 cells do not metastasize effi-
ciently because of a failure to acquire a fully invasive mesen-
chymal phenotype required for dissemination from the primary
site. Indeed, Id1 expression does not have an effect on breast
cancer cell intravasation or extravasation, early key steps in
the metastatic cascade (Gupta et al., 2007). Taken together,
our results demonstrate the ability of Id1 to endow breast cancer
Figure 2. Id1 Expression Is Associated with
an Epithelial Phenotype in Breast Cancer
Lung Metastases
(A and B) IHC of lung metastases from HMLER-
Twist cells injected mice reveals tumor cells pos-
itive for E-cadherin (A) and negative for Vimentin
(B). The scale bar represents 200 mm; inset scale
bar represents 100 mm.
(C) Id1 staining in HMLER-Twist lung metastases.
The scale bar represents 200 mm; inset scale bar
represents 100 mm.
(D) 4T1 cells form lung metastases positive for Id1
and E-cadherin and negative for Vimentin as
determined by IHC. The scale bar represents
500 mm; inset scale bar represents 100 mm.
(E) IHC for Id1, E-cadherin, and Vimentin in mac-
rometastases 5 days after 105 4T1 cells were
injected into the tail vein of Balb/c mice. The scale
bar represents 200 mm.
(F) Hematoxylin and eosin and E-cadherin staining
of human lung parenchyma showing two tumor
emboli of metastatic breast carcinoma.
(G) IHC for Id1 in lung metastasis of human breast
carcinoma.cells with TIC properties as defined by both in vitro and in vivo
assays independent of EMT induction.
Id1 Expression Correlates with an Epithelial Phenotype
in Pulmonary Metastases
Loss of Id1/Id3 expression in human breast cancer cells does not
affect extravasation from the circulation into the lung paren-
chyma but inhibits the generation of macroscopic colonies
(Gupta et al., 2007). Recent reports have demonstrated that
repression of EMT and the concomitant induction of MET is a
necessary step for successful lung colonization of cancer cells
(Korpal et al., 2011; Ocan˜a et al., 2012; Siemens et al., 2011;Cell Reports 5, 1228–1242, DeTsai et al., 2012). The observation that
Id1 expression correlates with an epithe-
lial TIC phenotype led us to hypothesize
that Id1 plays a role in facilitating MET
during lung colonization. To test this, we
used the metastatic breast cancer cell
line HMLER-Twist that has undergone
EMT due to ectopic expression of Twist
(Figure S2A). Orthotopic injections of
HMLER-Twist cells generated primary
tumors that maintained a mesenchymal
phenotype (Figure S2B). Two months
postinjection, the tumor-bearing mice
developed Twist-positive lung metasta-
ses (on average 4 ± 1 SD metastatic
lesions per lung) that had undergone
MET as seen by the acquisition of E-cad-
herin and loss of the Vimentin (Figures 2A,
2B, and S2C–S2E). The metastatic
colonies also showed strong nuclear
staining for Id1 (Figure 2C), supportingour hypothesis that Id1 correlates with an epithelial phenotype
during lung colonization.
To confirm the generality of our results, we examined Id1
expression in metastatic lesions derived from the murine mam-
mary cancer cell line 4T1 (Figure S2F). Mice injected orthotopi-
cally with 4T1 cells developed lung metastases positive for Id1,
the epithelial marker E-cadherin and negative for Vimentin (Fig-
ures 2D, S2G, and S2H). To confirm Id1 accompanies colony
initiation rather than solely proliferation in an established macro-
metastasis, we analyzed the presence of Id1 protein in early
metastatic lesions (5 days after injection). 4T1 cells formed on
average 12 ± 2 SD micrometastatic colonies exhibiting ancember 12, 2013 ª2013 The Authors 1231
Figure 3. Id1 Induces the Mesenchymal-to-
Epithelial Transition in Cells that Express
Twist but Not in Cells Expressing Snail
(A) Phase contrast images of HMLER-Twist cells
infected with a lentivirus carrying the ID1 gene
under a tetracycline regulatable promoter, without
(top panel) and with (bottom panel) the addition of
doxycycline to the growth media. IF for Id1 (left
column), E-cadherin (middle column), and the
Vimentin (right column). The scale bar represents
200 mm.
(B) Phase contrast images of HMLER-Snail cells
carrying the ID1 gene under a tetracycline regu-
latable promoter, without (top panel) and with
(bottom panel) the addition of doxycycline. IF for
Id1 (left column), E-cadherin (middle column), and
Vimentin (right column). The scale bar represents
200 mm.
(C) IHC of HMLER-Twist tumors reveals
Snail-positive cells near the invasive edge,
whereas no Snail protein is present in pulmonary
metastases (E).
(D) IHC of HMLER-Twist tumors for Id1. Purple
scale bar represents 500 mm; black scale bar
represents 200.
(E) IHC of HMLER-Twist pulmonarymetastases for
Snail. The scale bar represents 200 mm.epithelial morphology with uniform Id1 expression (Figure 2E).
We were able to corroborate our findings in patients of the
triple-negative breast cancer subtype (Figure 2F). All samples
were used according to the institutionally approved protocols.
Analysis of tissue microarrays (TMAs) containing 25 triple-nega-
tive lung metastatic lesions showed E-cadherin positivity in 23 of
25 samples (Table S1). Additionally, Id1 was detected in 7 of 25
samples, all of which were also positive for E-cadherin (Fig-
ure 2G; Table S1). Thus, Id1 expression correlates with epithelial
marker expression during early tumor initiation steps of breast
cancer colonization of the lungs.
Id Expression Induces MET in Twist-Expressing Cells
Because Id proteins act as dominant-negative regulators of
bHLH transcription factors, we hypothesized that Id1 antago-1232 Cell Reports 5, 1228–1242, December 12, 2013 ª2013 The Authorsnism of Twist controls the differentiation
state of breast cancer cells that have un-
dergone Twist-induced EMT. HMLER-
Twist cells were transduced with a
lentivirus expressing the tetracycline
transactivator driven by the Ubiquitin C
(UbC) promoter and the ID1 gene under
control of a tetracycline response
element (pTRIPZ TRE-Id1). In the pres-
ence of doxycycline, HMLER-Twist
TRE-Id1 cells show robust Id1 expres-
sion (Figures S3A and S4A) and undergo
MET as evidenced by the loss of their
mesenchymal morphology and re-
acquisition of E-cadherin and reduced
Vimentin expression (Figure 3A). Wewanted to determine if Id1 induction of MET depends on its abil-
ity to antagonize the Twist1 bHLH transcription factor. Snail
belongs to the zinc-finger family of transcription factors, lacks
the helix-loop-helix protein-binding motif, and therefore is not
antagonized directly by Id1. In contrast to HMLER-Twist cells,
Id1 overexpression did not lead to MET in cells that had under-
gone Snail-induced EMT (Figure 3B). These findings suggest
that Id1 does not induce MET in all mesenchymal cells, but
rather likely does so by specifically antagonizing bHLH tran-
scription factors, such as Twist.
A recent analysis of temporal and spatial expression of EMT
transcription factors in human breast cancer revealed that Snail1
is required for EMT initiation at the invasive edge of the primary
tumor, whereas Twist1 mainly acts to maintain EMT during later
stages of metastatic dissemination and possibly in dormant
Figure 4. Id1 Enhances the Colonization of
HMLER-Twist Cells via MET, but Not
HMLER-Snail Cells, In Vivo
(A) Schematic illustrating the tail vein injection of
HMLER-Snail TRE-Id1 or HMLER-Twist TRE-Id1
cells into immune-compromised host mice.
(B) Quantification of the number of macro-
metastases in the lungs of mice 3 weeks after
being injected with 105 HMLE-Ras Twist TRE-Id1
and HMLE-Ras Snail TRE-Id1 cells via tail vein (n =
5 for each group).
(C and D) Representative IF images of lungs from
mice injected with GFP+ HMLE-Ras Twist TRE-Id1
(C) and GFP+ HMLE-Ras Snail TRE-Id1 (D). Yellow
dashed lines encircle macrometastases, whereas
yellow circles encircle micrometastases. The
scale bar represents 500 mm.
(E and F) (E) Two representative IF images of GFP+
HMLE-Ras Twist TRE-Id1 macrometastases ex-
pressing E-cadherin (the scale bar represents
500 mm), whereas (F) GFP+ HMLE-Ras Snail TRE-
Id1 micrometastases (white arrows) do not
express E-cadherin. Purple scale bar represents
500 mm; red scale bar represents 100 mm.
(G) IF staining of GFP+ HMLE-Ras Snail TRE-Id1
micrometastases for Vimentin expression. The
scale bar represents 100 mm.micrometastases (Tran et al., 2011). We made a similar observa-
tion in HMLER-Twist tumors: Snail expression was confined to
the primary tumor at the invasive edge (Figure 3C) but was
absent from metastatic lesions in the lungs (Figure 3E). As ex-
pected, Twist was expressed in both primary tumor and metas-
tases (Figure S2C). Id1 was expressed in HMLER-Twist tumors
at the primary site (Figure 3D) in addition to the lung metastatic
site (Figure 2C). Interestingly, the Id1 staining pattern closely fol-
lowed Snail expression in the primary site (Figures 3C and 3D):
absent in the tumor center and present at the invasive edge.
Such spatial control may allow Id1 to exert its TIC and proproli-
ferative properties, whereas cells maintain their mesenchymal
character required for extravasation.Cell Reports 5, 1228–1242, DeId Expression Promotes Pulmonary
Metastasis via Induction of MET
We next sought to determine if Id1
expression with concomitant MET induc-
tion is sufficient to increase metastatic
colonization. HMLER-Snail TRE-Id1 and
HMLER-Twist TRE-Id1 cells were in-
jected into the tail veins of immune-
compromised mice, and, after 24 hr
when cells extravasated into the lung
parenchyma, the animals were placed
on a doxycycline feed diet in order to
induce expression of Id1 (Figures 4A,
S3A, and S4A). This allowed us to assess
the effect of Id1 specifically during the
early colonization stages of the metasta-
tic cascade. Similar levels of Id1 protein
expression were detected in cells that ex-travasated successfully in both HMLER-Twist- and HMLER-
Snail-injected animals (Figure S4B). However, only the lungs of
mice injected with HMLER-Twist Id1-overexpressing cells (Fig-
ures 4B, 4C, and S4C) contained macrometastases (on average
20 ± 4), whereas the lungs of mice injected with HMLER-Snail
Id1 cells contained only single cancer cells andmicrometastases
(Figures 4B and 4D). Consistent with what we observed in vitro,
the metastatic lesions formed by HMLER-Twist cells overex-
pressing Id1 underwent MET (Figure 4E), whereas HMLER-Snail
TRE-Id1 micrometastases did not (Figure 4F). The failure of
HMLER-Snail TRE-Id1 cells to undergo MET was further sup-
ported by the presence of Vimentin in the micrometastases (Fig-
ure 4G). We conclude that Id1 expression is sufficient to inducecember 12, 2013 ª2013 The Authors 1233
MET and promote colonization in Twist but not Snail-expressing
disseminated cells.
To determine if Id1 is necessary for MET during lung coloniza-
tion, HMLER-Twist cells with reduced Id1/Id3 levels were gener-
ated using previously validated short-hairpin RNA sequences
(Figures 5A and S5A) (Gupta et al., 2007). Knockdown of both
Id1 and Id3 was required due to a redundancy in function be-
tween the two proteins (Gupta et al., 2007; Perk et al., 2005).
The proliferation rate (Figure S5A) and mesenchymal
morphology (data not shown) of these cells were unaffected.
Although all the animals injected with the control HMLER-Twist
cells died within 60 days due to heavy lung metastatic burden
(Figure 5B), only one of five mice injected with HMLER-Twist
Id1/Id3 small hairpin RNA (shRNA) died due to pulmonarymetas-
tases (Figure 5B). Importantly, the lung metastatic lesions found
in the one deceased mouse stained positive for Id1, indicating
that metastases were derived from a subpopulation of cells
escaping the Id1 knockdown (Figure S5B). Metastases gener-
ated from control cells expressed E-cadherin (Figure 5C). Inter-
estingly, solitary cancer cells in the lungs that failed to transition
from micro- to macrometastases did not express E-cadherin
(Figure 5C, white arrows), indicating that HMLER-Twist cells
likely reach the lungs while retaining their mesenchymal pheno-
type. The lungs of mice injected with HMLER-Twist Id1/Id3
shRNA cells contained micrometastatic colonies, supporting
our previous finding that Id1/Id3 inhibition does not abrogate
the extravasation ability of metastasizing breast cancer cells
(Figure 5D) (Gupta et al., 2007). These micrometastatic colonies
also failed to express E-cadherin even when they reached col-
onies of approximately ten cells (Figure 5D, right panel). We
conclude that Id1/Id3 loss in metastasizing breast cancer cells
results in a failure to initiate MET. Although HMLER-Twist and
HMLER-Snail cells behave as bona fide TICs and are capable
of generating mesenchymal-like tumors at the primary site
from limited dilutions (data not shown) (Mani et al., 2008), our
studies suggest that tumor initiation in the lungs places addi-
tional requirements on the metastasizing cell, which are in part
fulfilled by the cell undergoing an MET. Thus, Id1 allows breast
cancer cells to retain their TIC phenotype while reacquiring their
epithelial character necessary for lung colonization.
Id1 Expression Is Regulated by TGF-b Signaling in
Mesenchymal-like Breast Cancer Cells
We next addressed the mechanism of Id1 regulation during met-
astatic progression. Our observation that Id1 is expressed at the
invasive edge (Figures 3D and 6A) of the primary tumor led us to
postulate that signals present at the tumor-stroma interfacewere
responsible for Id1 induction. A factor implicated in switching
cancer cells from a cohesive epithelial state into a mesenchymal
migratory phenotype is the cytokine TGF-b (Massague´, 2012).
TGF-b pathway activation in primary breast tumors is associated
with increased risk of lung metastases (Padua et al., 2008). The
same study showed TGF-b upregulation of Id1 in cells isolated
from pleural fluids of patients with metastatic breast cancer.
These findings prompted us to explore the potential link between
Id1 expression and TGF-b activity. Activation of the TGF-b
pathway in 4T1 breast tumors was detected by nuclear accumu-
lation of phosphorylated Smad2/Smad3 and followed a similar1234 Cell Reports 5, 1228–1242, December 12, 2013 ª2013 The Autalthough broader localization pattern as Id1-positive cells: stain-
ing wasmostly at the invasive edge of the tumor and absent from
the center of the tumor (Figures 6A and 6B). Importantly, the
tumor invasive edge is where cells initially undergo EMT and
acquire a migratory phenotype as evidenced by positive Vimen-
tin staining (Figure S6A).
Previous work demonstrated that TGF-b represses Id1 in
nontumorigenic human epithelial cell lines (Kang et al., 2003),
whereas in some cancer cells TGF-b induces Id1 expression
(Anido et al., 2010; Padua et al., 2008). Using cells isolated
from the pleural effusions of patients with advanced breast
cancer of the triple-negative subtype (Gomis et al., 2006)
(CN37 and CN34 cell lines), we found that TGF-b treatment
leads to an increase in Id1 protein levels (Figure 6C). Continued
treatment with TGF-b did not result in Id1 inhibition (Figure 6C),
although a dampening of the effect was seen that could be
reversed by the addition of fresh TGF-b (data not shown). To
further characterize Id1 responsiveness to TGF-b, a panel of
breast cancer cell lines categorized as either of luminal or basal
subtype were employed. Id1 induction in response to TGF-b
was detected only in those belonging to the basal-like subtype
(BT- 549, MDA-MB-157, MDA-MB-231, and MDA-MB- 435)
(Figure 6D), whereas no Id1 induction was observed in MCF-7
and MDA-MB-361 luminal breast cancer cells (Figure 6E)
(Finn et al., 2009). Because most basal-like cell lines are cate-
gorized as post-EMT due to expression of Vimentin, we hypoth-
esized that the effect of TGF-b on Id1 expression may be
dependent on the mesenchymal state of the cell. Indeed,
whereas TGF-b did not induce Id1 in the epithelial parental
cell line (HMLE), Id1 was upregulated in both mesenchymal
derivatives (HMLE-Snail and HMLE-Twist) (Figures 6F and
S6B). Collectively, these results suggest a link between the
acquisition of mesenchymal characteristics and a switch in
the Id1 response to TGF-b.
Given that both TGF-b and Id1 are inducers of TIC properties in
breast cancer cells, we sought to determine if Id1 is a critical
mediator of TGF-b activity. TGF-b treatment of mammospheres
resulted in significant upregulation of Id1 mRNA (Figure 6G)
demonstrating that Id1 remains under TGF-b control during
mammosphere formation. Id1 and phosphorylated Smad2/
Smad3 were present in HMLE-Twist mammospheres (Figures
6H and 6I) consistent with the finding that endogenous TGF-b
governs the TIC phenotype in breast cancer cells, which could
be Id1/Id3 mediated (Scheel et al., 2011; Shipitsin et al., 2007).
Consistent with this hypothesis, knockdown of Id1/Id3 led to
fewer mammospheres formed by HMLE-Twist cells (Figure 6J).
Inhibition of TGF-b by a small molecule inhibitor SB-431542
led to decreased pSmad2/pSmad3 levels in HMLE-Twist cells
(Figure S6B) and a reduced ability of HMLE-Twist cells to form
mammospheres (Figure 6K). To determine if TGF-b governs
the TIC phenotype via Id1 induction, HMLE-Twist cells over-
expressing Id1 were treated with TGF-b inhibitor. Indeed, Id1
overexpression partially rescued the mammosphere formation
potential suggesting that induction of Id1 by TGF-b is partly
sufficient for this process (Figure 6K). Altogether, these results
indicate that Id1 upregulation by TGF-b is necessary and
sufficient for the acquisition of TIC phenotype in cultured breast
cancer cells.hors
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(D) Two representative IF images from the lungs of a mouse injected with GFP+ HMLE-Ras Twist Id1/Id3 short-hairpin cells. Yellow arrows point to E-cadherin-
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Figure 6. Id1 Is Induced by TGF-b in Breast Cancer Cell Belonging to the Basal Subtype and Is Required for TGF-b Induction of TICs
(A) IHC for Id1 shows Id1-positive cells present at the invasive edge of 4T1 tumor allografts from mammary fat pads of C57BL/6 mice. The scale bar represents
200 mm.
(legend continued on next page)
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Id1 Is Regulated by the Canonical Smad-Dependent
TGF-b Pathway and Requires the Activity of CBP/p300
Coactivators
TGF-b-driven induction of Id1 was abrogated by treatment of
CN37 cells with either actinomycin D or cycloheximide, demon-
strating that Id1 upregulation occurs at the level of transcription
and requires de novo protein synthesis (Figures S7A and S7B).
TGF-b transduces signals through a heterodimeric receptor
complex formed by the type I (TbRI) and the type II (TbRII) recep-
tors. In the case of canonical TGF-b signaling, the activated
receptor complex phosphorylates Smad2 and Smad3 transcrip-
tion factors, which results in their binding to Smad4 and translo-
cation to the nucleus where they regulate the transcription of
target genes (Massague´, 2012). To confirm that Id1 induction
is mediated by TGF-b receptors, cells were treated with TGF-
bRI inhibitor, SB-431542, which resulted in a complete block
of Id1 upregulation by TGF-b (Figures 7A and S6B). Deletion
analysis of the Id1 promoter containing a luciferase reporter
(Lo´pez-Rovira et al., 2002) identified the 1,046 to 863 bp
region as necessary for Id1 induction (Figures 7B and S7C).
Interestingly, this sequence containing the Smad-binding
element (SBE) is the same promoter region responsible for Id1
downregulation by TGF-b in normal epithelial cells (Kang et al.,
2003). To examine the potential contribution of different Smads,
individual knockdowns of Smad2, Smad3, and Smad4 were per-
formed (Figures 7C–7E). Smad2 inhibition did not block Id1
induction (Figure 7C), whereas the knockdown of either
Smad3 or Smad4 prevented the Id1 response to TGF-b (Figures
7D and 7E).
Id1 repression by TGF-b in normal epithelial cells is dependent
on the transcriptional repressor ATF-3 (Kang et al., 2003). We
observed that TGF-b still leads to the induction of ATF-3 protein
in breast cancer cells (Figure 7F). Moreover, even after overex-
pression of ATF-3, TGF-b still maintains the ability to upregulate
Id1, arguing that the effect of TGF-b is independent of low levels
of ATF-3 protein (Figure 7F).
Smad complexes have the ability to recruit a wide variety of
cofactors, which allow Smads to elicit a wide range of tissue-
specific responses. One of the known regulators of TGF-b
signaling are coactivators CBP and p300 proteins, which in addi-
tion to acting as transcriptional activators also possess histone
acetyltransferase activity. A recent report has implicated the
importance of CBP/p300 in TGF-b-mediated transcription of
target genes in Vimentin-positive mesangial cells (Yuan et al.,
2013), prompting us to explore the role of these coactivators in(B) IHC for pSmad2/pSmad3 in 4T1 primary tumor allografts. The scale bar repre
(C) CN37 and CN34 cells were treated with 100 pm TGF-b for the indicated time pe
of Id1, pSmad2, and actin were determined by immunoblot.
(D and E) Id1 response to TGF-bwas evaluated in a panel of breast cancer cell lines
to western blot analysis.
(F) HMLE, HMLE-Snail, and HMLE-Twist cells were serum starved for 3 hr before
actin were determined by immunoblot.
(G) Quantification of Id1 mRNA by quantitative RT-PCR in HMLE-Twist mammos
(H) IHC for pSmad2/pSmad3 in HMLE-Twist mammosphere. The scale bar repre
(I) IHC for Id1 in HMLE-Twist mammosphere. The scale bar represents 200 mm.
(J) Quantification of mammospheres formed by HMLE-Twist cells and HMLE-Tw
(K) Quantification of mammospheres formed by HMLE-Twist cells, HMLE-Twist c
overexpressing Id1 with or without the TGF-b inhibitor.
Cell ReTGF-b upregulation of Id1 in mesenchymal cells. Due to the
redundant roles of CBP and p300, we used MEFs carrying
homozygous conditional knockout alleles of both CBP and
p300 (double-knockout or dKO MEFs) (Kasper et al., 2010).
Because MEFs express mesenchymal markers, we postulated
that in this cellular context TGF-b induces Id1. As expected,
TGF-b stimulation of nontransduced MEFs and those trans-
duced with GFP control (Ad-GFP) led to strong upregulation of
Id1. However, cells transduced with Cre recombinase (dKO
MEFs), which lost the expression of both CBP and p300, failed
to induce Id1 following TGF-b treatment (Figure 7G). Thus, these
results demonstrate that TGF-b-mediated Id1 upregulation
requires the activity of the CBP/p300 coactivators.
In summary, upregulation of Id1 by TGF-b in breast cancer re-
quires a transition to a mesenchymal state, which manifests at
the periphery of the primary tumor and primes the Id1 promoter
for activation by canonical Smad3/Smad4 signals in combina-
tion with CBP/p300. As described above, upregulation of Id1 is
essential for the eventual colonization of the lung metastatic site.
DISCUSSION
Recently published studies support the notion that the epithelial
to mesenchymal transition plays an important role in carcinoma
metastasis (Thiery et al., 2009). Although the bulk of the primary
tumor is constrained by epithelial attachments, mesenchymal
cells have an enhanced ability to migrate and traverse the bar-
riers of endothelial cell junctions. This ability facilitates entry
and exit from the circulation, critical steps in metastatic progres-
sion. The observation that induction of EMT in breast tumor cells
by forced expression of the transcription factors Snail and Twist
was associated with the enhancement of tumor sphere forma-
tion and the expression of stem-like markers suggested the
EMT transition also endows these cells with tumor initiating
capacity (Mani et al., 2008). This concept connected the cell
migration traits with the TIC programs such as the ability to colo-
nize the metastatic site and potentially confer drug resistance. It
appears now however that EMT and TIC properties are not
always inextricably linked: loss of the homeobox protein Prrx1
was found to be required for metastatic colonization of BT-549
breast cancer cells, and such loss is associated with a mesen-
chymal to epithelial transition (MET) and the acquisition of TIC
capacity (Ocan˜a et al., 2012). Additionally, forced repression of
Twist protein at the metastatic site was shown to be associated
with epithelial differentiation and enhanced colonization. Thus,sents 100 mm.
riods. Cells were serum starved for 3 hr prior to TGF-b treatment. Protein levels
classified either as basal (D) or luminal subtype (E). Total protein was subjected
being treated with 100 pM TGF-b for 3 hr. Protein levels of Id1, pSmad2, and
pheres following the treatment with 100 pM TGF-b for 3 hr.
sents 200 mm.
ist cells expressing RNA short hairpins for Id1 and/or Id3.
ells treated with the TGF-b inhibitor SB-431542 (2 mM), and HMLE-Twist cells
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Figure 7. TGF-b Induces Id1 Expression
through Smad-Dependent Pathways and
Requires the CBP/p300 Coactivator
(A) CN37 cells were treated with 100 pM TGF-b for
3 hr in the absence or presence of 2 mM TbRI in-
hibitor SB431542. Levels of Id1, pSmad2, and
actin were determined by western blot.
(B) Luciferase reporter activity characterizing the
minimal ID1 gene promoter region necessary for
Id1 induction by TGF-b. CN37 cells were trans-
fected with indicated Id1 reporter constructs and
treated with or without TGF-b for 20 hr.
(C–E) Immunoblots with the indicated antibodies
were carried out using CN37 cells transfected with
control, Smad2 (C), Smad3 (D), or Smad4 shRNA
(E) in the presence or absence of TGF-b for 3 hr.
(F) CN37 cells were transduced with vector control
or lentivirus expressing ATF-3 and treated with or
without TGF-b. ATF-3 protein levels were deter-
mined by western blot.
(G) Western blot of mouse embryonic fibroblasts
(MEFs) with the floxed CBP/p300 gene infected
with control GFP+ adenovirus (Ad-GFP) or virus
carrying Cre recombinase (Ad-GFP-Cre) and
treated with TGF-b.the recent evidence not only uncouples ‘‘stemness’’ character
from EMT, but also further fosters the notion that in order to
form macrometastases, migrating cancer cells need to undergo
MET. Therefore, understanding what contextual signals trigger
MET is critical for understanding the underlying mechanism
of metastatic progression and the development of improved
clinical approaches.
Recent reports have elucidated some of the mechanisms that
regulate MET, including the dynamic regulation of EMT-specific
factors during the metastatic cascade. Snail1 is specifically
required for EMT initiation at the invasive edge of primary tumors
and high Snail1 expression in primary tumors relative to corre-
sponding metastases correlates with distant relapses (Blanco1238 Cell Reports 5, 1228–1242, December 12, 2013 ª2013 The Authorset al., 2002; Peinado et al., 2004; Tran
et al., 2011). Similarly, we observe Snail
expression only at the invasive edge of
the HMLER-Twist primary tumors.
Conversely, Twist1 is dispensable for
EMT initiation and Snail1 expression re-
presses Twist1 transcription directly dur-
ing Snail-induced EMT (Tran et al., 2011).
Twist1 was shown to mainly act to main-
tain the EMT state in later stages of
metastasis, and, whereas Twist1 expres-
sion in the primary tumors does not corre-
late with distant recurrence, high Twist1
expression in breast cancer bone marrow
disseminated tumor cells is strongly
associated with metastatic recurrences
(Tran et al., 2011). A potential mechanism
for how Snail expression is lost during
metastatic colonization is provided by
studies identifying micro-RNAs thattarget transcripts of various EMT factors for degradation and
lead to induction of MET (Kim et al., 2011; Siemens et al.,
2011). In particular, Snail and Zeb1/Zeb2 zinc finger transcrip-
tion factors have been shown to be downregulated by miRNAs
34 and 200, respectively, which may contribute to their regula-
tion in vivo (Burk et al., 2008; Korpal et al., 2008; Siemens
et al., 2011). However, how other critical EMT transcriptional
factors, such as bHLH factor Twist, are downregulated to allow
for MET and colonization remains unclear. The studies pre-
sented here suggest that this is accomplished by the domi-
nant-negative transcription factor Id1, which opposes Twist
activity likely by direct protein-protein interactions (Figure 8)
(Spicer et al., 1996).
Figure 8. Proposed Model for Id1 Induced MET during Metastatic
Colonization of Lungs by Breast Cancer Cells
Integral for themetastatic dissemination of carcinoma cells is the acquisition of
an invasive phenotype via induction of EMT. A key cytokine present at the
tumor-stroma boundary, TGF-b, induces the EMT transcription factor Snail,
which changes the Id1 response to TGF-b in disseminating cells. TGF-
b-mediated induction of Id1 is dependent on Smad3/Smad4 and CBP/p300
cofactors. Id1 expression in the primary tumor does not revert Snail-induced
EMT, which allows Id1-expressing cells to complete the steps required for
dissemination: intravasation, survival in circulation, and extravasation. In the
circulation, platelet-derived TGF-b continues to upregulate Id1. At the meta-
static site, where Snail is absent, Id1 opposes the activity of EMT transcription
factor Twist. Such inhibition leads to MET and the colonization of distant
organs.We also present evidence supporting a role for Id1 in endow-
ing breast cancer cells with a TIC phenotype that is independent
of EMT and show the TIC phenotype correlates with the ability to
initiate tumor growth at the secondary site. Id1 expressing TICs
retain an epithelial character and, importantly, are capable of
initiating tumor growth both in mammary fat pads and during
colonization of the lung parenchyma. We show here that,
whereas high levels of Id1 are present at the invasive edge of pri-
mary breast tumors, cells can retain the mesenchymal charac-
teristics induced by Snail because Id1 does not have the ability
to counter the activity of this factor. TGF-b-mediated induction
of Snail and EMT at the primary site makes the Id1 promoter
receptive to TGF-b upregulation. In the bloodstream, platelets
are the major source of TGF-b, and platelet-specific loss of
TGF-b is sufficient to prevent metastasis (Labelle et al., 2011).
Thus, we speculate that, in the circulation, TGF-b continues to
induce Id1 and themesenchymal state remains under the control
of Snail1.
We show that TGF-b upregulates Id1 through the combined
action of Smad3/Smad4 and CBP/p300. In addition to being
transcriptional coactivators, CBP/p300 possess intrinsic histone
acetyltransferase activity (HAT) that modifies lysine residues of
the core histone tails (Ogryzko et al., 1996). Thus, it is possible
that CBP/p300-driven acetylation of Id1 promoter histones
inhibits binding of ATF-3 to the Id1 promoter while recruiting
Smad3 for transcriptional activation of Id1. CBP/p300 have
been demonstrated to acetylate nonhistone substrates, such
as Smad3, raising the possibility that, similar to other context-
dependent modifications of Smad proteins, acetylation may be
an additional mechanism of regulatory control. Finally, a small-Cell Remolecule inhibitor of p300 was shown recently to induce cyto-
toxicity and suppress tumor growth specifically in triple-negative
cell lines (Yang et al., 2013). These results are consistent with our
data suggesting a role of CBP/p300 in mesenchymal breast
cancer cells.
Upregulation of Id1 at the primary site may contribute to the
enhanced primary tumor growth observed in breast cancer
models due to its enhanced TIC properties and/or opposition
to cell-cycle inhibitors such as p16 and p21 (O’Brien et al.,
2012; Ohtani et al., 2001). In addition, upregulation of Id1 primes
the cells for the eventual conversion back to the epithelial state
via antagonism of Twist at the secondary site. Human samples
of squamous cell carcinoma metastases often display strong
Twist protein expression (Merikallio et al., 2011), and in human
breast cancer Twist expression is present in disseminated tumor
cells. In animal models used in our studies, Twist protein expres-
sion is present in metastatic colonies. However, we show that
Twist activity is opposed by Id, leading to the induction of MET
and the conversion of disseminated premetastatic tumor cells
into macrometastatic colonies. Thus, our study provides insight
as to how one of the critical EMT inducers is inhibited to facilitate
the formation of metastases.
We speculate that the maintenance of the TIC state after
extravasation, at least in part mediated by Id1, is essential for
early colonization because sphere formation assays (which
define TICs) likelymimic the growth conditions for small numbers
of cells in a nonadherent milieu prior to colonization. Once initi-
ated, epithelialization is then required for the formation of macro-
scopic colonies, possibly by reversion of the growth inhibitory
properties of the mesenchymal state (Brabletz et al., 2001).
Such phenotypic plasticity between EMT and MET states has
been proposed as an essential trait of malignant cells completing
all the complex steps of themetastatic cascade in some cancers
(Brabletz, 2012; Scheel and Weinberg, 2012). Recent work
demonstrating tumor-initiating cell plasticity, as evidenced by
conversions between a non-TIC and a TIC phenotype within
basal breast cancer cells, further supports phenotypic plasticity
during cancer metastasis (Chaffer et al., 2013).
Relevance to Human Disease
Id1 expression and the TGF-b-responsive gene signature corre-
late with poor prognosis in the triple-negative subtype of breast
cancer (Buck et al., 2004; Gupta et al., 2007). These tumors
exhibit metaplastic morphology, mostly belong to the claudin-
low subtype, and are mesenchymal in character at the primary
site (Gupta et al., 2007; Perk et al., 2006). Therefore, our
results showing Id1 induction of MET in claudin-low cell lines
(HMLER-Twist) (Morel et al., 2012) during colonization and the
requirement for this transition in animal models of metastasis
suggest our results may be relevant to human breast cancer
metastasis. Indeed, using human tissue microarrays of matched
lung metastases obtained from patients with triple-negative
breast tumors, we show that, although primary tumors are asso-
ciatedwithmesenchymal features, their correspondingmetasta-
ses display strong E-cadherin expression, suggesting the impor-
tance of epithelial traits in humanmetastatic colonization. Strong
Id1 expression was detected in 7 of 25 human breast cancer
metastases suggesting Id1 may be essential for the formationports 5, 1228–1242, December 12, 2013 ª2013 The Authors 1239
of some but not all metastases or that Id1 expression may be
transient. We also note that the requirement for MET during met-
astatic colonization might not be universal as some tumor types
retain their mesenchymal character at the secondary site (Achar-
yya et al., 2012).
The importance of targeting different populations of human tu-
mor cells that play different roles in tumor relapse and responses
to therapy has been established as an important future step in
cancer drug development (Singh and Settleman, 2010). The
compound salinomycin acts as a potent inhibitor of tumor
growth in mouse tumor models by specifically targeting the
mesenchymal, TIC subpopulation (Gupta et al., 2009).
However, our results point toward the existence of different pop-
ulations even within the bounds of the tumor initiating cell pheno-
type that play different roles in the metastatic cascade and may
be important to target as well. That is, colonizing epithelial-TICs
might be important cells to target for effective metastasis inter-
vention. Given that distant organ colonization is the ultimate
cause of death for most breast cancer patients, developing
drugs that target this particular phase of metastasis is of para-
mount importance.EXPERIMENTAL PROCEDURES
Cell Culture and Reagents
MCF-7, MDA-MB-157, MDA-MB-231, MDA-MB-361, MDA-MB-435, and
BT-549 tumor cell lines and HMLE cell lines were cultured as described in Sup-
plemental Information. CN37 and CN34 cells were isolated from the pleural
effusion of patients with metastatic breast cancer (Gomis et al., 2006).
HMLE (immortalized human mammary epithelial cells) and HMLER (V12H-
Ras transformed HMLE cells) were a kind gift from Robert Weinberg (Elenbaas
et al., 2001). CBP/p300 dKO MEFs were a generous gift from Paul Brindle.
TGF-b1 (R&D Systems), SB431542 (Sigma-Aldrich), cycloheximide (Sigma-
Aldrich), and actinomycin D (Sigma-Aldrich) were used as indicated.
Additional experimental procedures can be found in the Supplemental
Information.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and one table and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2013.11.014.
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